Patents
Patents for C07D 233 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings (34,408)
08/2005
08/18/2005WO2005075413A1 Method for producing guanidinium salts
08/18/2005WO2005047242A3 Compounds containing thiosulfate moieties
08/18/2005WO2005040345A3 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
08/18/2005WO2005030794A3 Hemiasterlin derivatives and uses thereof
08/18/2005WO2004100873A3 Compounds, compositions, and methods
08/18/2005WO2004092224A3 Polymerisation initiator system
08/18/2005US20050182110 tetracylic bridged ring compounds such as 9-nitro-11-amino-11-((imidazol-2-yl)aminocarbonyl)-9,10-dihydro-9,10-ethanoanthracene; treating obesity, diabetes and inflammatory or immune associated diseases; nuclear factor kappa beta (NF-KB)
08/18/2005US20050180953 peptides derivatives as an agent inducing cells differentiation and in particular, to their use in antitumor noncytotoxic therapy; melanoma; most preferred compound used in the present invention is 4-[N-(2-imidazol-4-yl)ethyl)carbamoyl]butyric acid (Dicarbamine (reg) )
08/18/2005DE102004001413A1 3-Hydroxymethyl-4-Hydroxy-Phenyl-Derivate zur Behandlung von chronisch obstruktiver Lungenerkrankung 3-hydroxymethyl-4-hydroxy-phenyl derivatives for the treatment of chronic obstructive pulmonary disease
08/18/2005CA2554809A1 Novel n-alkyl thiourea-and thioamide-substituted imidazolyl inhibitors and glutaminyl cyclase
08/18/2005CA2554796A1 Modulators of atp-binding cassette transporters
08/17/2005EP1564200A1 Ketone compounds and compositions for cholesterol management and related uses
08/17/2005EP1562924A1 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
08/17/2005EP1562923A1 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
08/17/2005EP1562910A1 Celecoxib prodrug
08/17/2005EP1562895A1 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
08/17/2005EP1202945B1 Methods for preparing perfluorinated [18 f]-radiolabelled nitroimidazole derivatives for cellular hypoxia detection
08/17/2005CN1656109A Non nucleoside reverse transcriptase inhibitors
08/17/2005CN1655773A Compounds useful in the treatment of anthrax and inhibiting lethal factor
08/17/2005CN1654455A Dihalopropene compounds, insecticidal/acaricidal agents containing same, and intermediates for their production
08/17/2005CN1215055C Arylsulfonamido-substituted hydroxamic acid derivatives
08/16/2005US6930076 Nematicidal trifluorobutenyl imidazole thioether derivatives
08/11/2005WO2005072729A1 Modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof
08/11/2005WO2005072132A2 TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF
08/11/2005WO2005072082A2 2-guanidinylimidazolidinedione compounds and methods of making and using thereof
08/11/2005WO2005058840A3 Method of coloring with capped diazotized compound and coupling component
08/11/2005WO2005023422A3 Production and use of ionic liquids containing thiocyanato anions
08/11/2005WO2004110983A8 New benzamides as pparϒ modulators
08/11/2005WO2004014847A8 Mcp-1 receptor antagonists and method of use thereof
08/11/2005US20050176828 Polyamine acylated with a hydrophobic acyl group, where acylation is by formation of either an amide or a sulfonamide linkage; antiproliferative agents; inhibition of cellular polyamine synthesis, even in the presence of exogenously supplied spermidine to inhibit cell growth and proliferation
08/11/2005US20050176821 Meta-substituted phenylene sulphonamide derivatives
08/11/2005US20050176766 2,3-Oxidosqualene-lanosterol cyclase inhibitors
08/11/2005US20050176647 Having an alkylation site via a vinyl linker at the end of a pyrrole-imidazole polyamide; inhibits the expression of a specific gene; high anti-cancer activity
08/11/2005US20050175867 Room-temperature molten salt, process for producing the same and applications thereof
08/11/2005DE102004003958A1 Herstellungsmethode für ionische Flüssigkeiten Method of preparation of ionic liquids
08/11/2005DE102004003811A1 Substituierte N-Cyclohexylimidazolinone, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel Substituted N-Cyclohexylimidazolinone, processes for their preparation and their use as medicaments
08/10/2005EP1561749A1 TNF-Alpha production inhibitors for the treatment of autoimmune diseases
08/10/2005EP1561741A1 Method for deuteration or tritiation of heterocyclic ring
08/10/2005EP1333795A4 Novel coupler for use in oxidative hair dyeing
08/10/2005CN1653052A Novel imidazole compounds, method for preparing same and use thereof as medicines
08/10/2005CN1652775A Peptide deformylase inhibitors
08/10/2005CN1651443A Monophosphine ligand having C2 symmetric skeleton, synthesis method and application
08/10/2005CN1651415A Preparation and purification method of ornidazole optical antipode
08/10/2005CN1214012C Method for producing carbonyl dimidazoles
08/10/2005CN1214004C Process for producing arylsulfenyl halide
08/09/2005US6927232 Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles
08/09/2005US6927227 Heterocyclic containing biphenyl aP2 inhibitors and method
08/09/2005CA2303217C Use of an angiotensin ii receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients
08/04/2005WO2005070898A1 Substituted n-cyclohexyl imidazolinones having an mch-modulatory effect
08/04/2005WO2005070897A1 High purity butoconazole nitrate with specified particle size and a process for preparation thereof
08/04/2005WO2005070896A1 Mehtod for producing ionic liquids
08/04/2005WO2005054179A3 Hydroxamic acid esters and pharmaceutical use thereof
08/04/2005WO2005041853A3 Antibacterial and/or antiprotozoal nitroimidazole derivative compounds with urease inhibitor activity, process for preparing these compounds and use in pharmaceutical compositions and medicines.
08/04/2005WO2005040355A3 Tao kinase modulators and methods of use
08/04/2005WO2004092135A3 Substituted benzosulphonamide as potentiators of glutamate receptors
08/04/2005US20050171163 MCP-1 receptor antagonists and methods of use thereof
08/04/2005US20050171154 Carboxylic acid amides
08/04/2005US20050171136 Modulators of the glucocorticoid receptor and method
08/04/2005US20050171096 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
08/04/2005US20050171081 1,3-bis(phenylmethyl)-4,5-dimethyl-1H-imidazlium chloride; 1,3-bis(phenylmethyl)-2,4,5-trimethyl-1H-imidazolium chloride; anticancer; antiproliferative; high yield and purity
08/04/2005CA2554233A1 Substituted n-cyclohexyl imidazolinones having an mch-modulatory effect
08/03/2005EP1559718A1 Combretastatin A-4 phosphate prodrug salts with nitrogen-containing compounds
08/03/2005EP1559709A1 Heterocycle-containing carboxylic acid derivative and drug containing the same
08/03/2005EP1558594A2 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
08/03/2005EP1558583A1 Novel phenylethanolamine derivatives and the use of the same as beta-3-agonists
08/03/2005EP1558082A1 Biocidal composition containing halogenated hydantoin and paraffin wax
08/03/2005EP1357124B1 Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient
08/03/2005CN1649885A Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such
08/03/2005CN1649847A Method for producing optically active sulfoxide derivative
08/03/2005CN1649846A Compounds of the family of 3-alkyl-(4, 5-diphenyl-imidazol-1-yl) and their use as soothing agents
08/03/2005CN1649831A Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient
08/03/2005CN1649830A Substituted aryl ketones
08/03/2005CN1649829A Novel florfenicol-type antibiotics
08/03/2005CN1649827A Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids
08/03/2005CN1649820A Compounds that modulate PPAR activity and methods for their preparation
08/03/2005CN1649612A Induction method for cell differentiation
08/03/2005CN1649603A Aqueous compositions containing metronidazole
08/03/2005CN1649582A Amino-methyl substituted tetracycline compounds
08/03/2005CN1213044C Amine and amide derivatives as ligands for neuropeptide YY5 receptor useful in treatment of obesity and other disorders
08/03/2005CN1213038C Benzophenones as inhibitors of reverse transcriptase
08/03/2005CN1213037C Halogenated pyrimidine and its application for reducing parasite
08/03/2005CN1213025C 硫代酰胺衍生物 Thioamide derivatives
08/03/2005CN1213020C Phenylalaninol derivatives
08/02/2005US6924396 α-haloenamine reagents
08/02/2005US6924377 Etherifying mucochloric or mucobromic acid with an alcohol, alkylation, hydrogenation, dehydrochlorination or dehydrobromination, decyclization by reductive amination and carboxylation; 3-Aminomethyl-5-methyl-hexanoic acid
08/02/2005US6924376 Compounds, compositions and methods
08/02/2005US6924330 Thioimidazolidine derivatives as light stabilizers for polymers
08/02/2005US6924251 herbicides.
08/02/2005CA2254972C Process for the preparation of 1-alkoxycarbonyl-3-phenylpropyl derivatives
08/02/2005CA2170020C Retroviral protease inhibiting compounds
08/02/2005CA2102960C Method of treating colon disturbances with pharmaceutical compositions containing imidazol-1-yl compounds
07/2005
07/28/2005WO2005068445A2 Pesticidal heterocyclic dihaloallyl compounds
07/28/2005WO2005068432A1 Malononitrile compound as pesticides
07/28/2005WO2005068423A1 Malononitrile compound and use thereof
07/28/2005WO2005068420A1 Urea and thiourea compounds and compositions for cholesterol management and related uses
07/28/2005WO2005068418A1 Sulfide and disulfide compounds and compositions for cholesterol management and related uses
07/28/2005WO2005068412A1 Ketone compounds and compositions for cholesterol management and related uses
07/28/2005WO2005068410A1 Ether compounds and compositions for cholesterol management and related uses
07/28/2005US20050165106 Preferentially inhibit the inducible isoform of nitric oxide synthase
07/28/2005US20050165078 evolution of ammonia is virtually completely avoided; reduction in sublimation of urea, as occurs on reaction in the melt; high purity of the crude product means that further recrystallization is usually unnecessary